- Tixagevimab/cilgavimab, sold
under the
brand name
Evusheld, is a
combination of two
human monoclonal antibodies,
tixagevimab (AZD8895) and
cilgavimab (AZD1061)...
-
emergency use
authorization (EUA) of the
antibody drug tixagevimab/cilgavimab (
Evusheld) to
prevent COVID-19 in
immunocompromised people who
cannot be
fully vaccinated...
- support. On 7 April, the
Health Ministry approved the use of AstraZeneca's
Evusheld 100mg/ml
solution for
treating COVID-19 patients. On 11 April,
Kedah state's...
-
treatment of
autoimmunity and a half-life
extended antibody ****tail (
Evusheld) with 'YTE'
mutations is used for the
prophylaxis of SARS-CoV2. Engineering...
-
announced that it had
granted interim authorisation for AstraZeneca's
Evusheld COVID-19
treatment drug for use in Singapore, for
those medically ineligible...
- the
Omicron variant. Tixagevimab/cilgavimab, sold
under the
brand name
Evusheld, is a
combination of two
human monoclonal antibodies,
tixagevimab (AZD8895)...
-
shielded from COVID-19 for two and a half
years has
spent more than £2,000 on
Evusheld (a drug not
available on the NHS) to
improve her immunity. The
Welsh Government...
- neutralization" by vaccines,
including the new
Omicron boosters. Key
antibody drugs,
Evusheld and bebtelovimab, are "completely inactive"
against the new subvariants...
- first.
Fifteen people are
hospitalized in the UK. The
antibody treatment Evusheld produced by
AstraZeneca is
shown to
retain neutralising activity against...
-
Singapore had
concluded a
purchase agreement with
AstraZeneca for its
Evusheld COVID-19
treatment drug, with the
first shipment to
arrive at the end of...
